Log in to search using one of your social media accounts:

 

U.S. jury sides with Amphastar over Momenta in drug patent trial
BOSTON (Reuters) - A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Oral Apixaban Safe for Thromboprophylaxis Before Surgery in Gynecologic Cancers
Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies. (Source: CancerNetwork)
Source: CancerNetwork - March 17, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Cancer Complications Gynecologic Cancers News Conferences/SGO 2017 Source Type: news

Lovenox (Enoxaparin Sodium Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 11, 2017 Category: Drugs & Pharmacology Source Type: news

Enoxaparin preferred option for VTE prevention after THR in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2016 Category: Drugs & Pharmacology Source Type: news

Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX
The finding in patients hospitalized for acute illness was said to be"a wake-up message" that even those admitted for ischemic stroke or heart failure are at special risk for thrombosis."Heartwire from Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 29, 2016 Category: Intensive Care Tags: Cardiology News Source Type: news

ENSURE-AF Trial Supports Edoxaban for Electrical Cardioversion
ROME — Results of the largest-ever randomized clinical trial of anticoagulation for electrical cardioversion of patients with nonvalvular atrial fibrillation demonstrate that edoxaban is a safe, effective, and convenient alternative to the standard strategy of enoxaparin as a bridge to warfarin. (Source: Caring for the Ages)
Source: Caring for the Ages - September 29, 2016 Category: Health Management Authors: Bruce Jancin Source Type: news

Blood Clots, Deep Vein Thrombosis and Pulmonary Embolism
What is Deep Vein Thrombosis (DVT)? DVT is the formation of a blood clot (thrombus) within a deep vein. The deep veins pass through deep tissues and muscles. Muscle contractions (walking, running, activity, etc.) squeeze blood through the deep veins to the heart. The deep veins have valves which prevent blood from flowing back to the ankles and feet. The majority of blood clots are small and are usually broken down or dissolved. Large clots may form and can block the vein causing the patient to complain of pain and swelling. Homan's sign is not very specific. High index of suspicion is necessary for diagnosis. Virchow'...
Source: Healthy Living - The Huffington Post - August 17, 2016 Category: Consumer Health News Source Type: news

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa < sup > ® < /sup > (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery
No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa ® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Enoxaparin Adjustment Curbs Thromboembolism in Trauma PatientsEnoxaparin Adjustment Curbs Thromboembolism in Trauma Patients
In trauma patients, compared to use of standard prophylactic doses of enoxaparin sodium, dosage adjustment prompted by anti-factor Xa (anti-Xa) trough levels may reduce venous thromboembolism (VTE), according to California-based researchers. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 15, 2016 Category: Surgery Tags: Emergency Medicine News Source Type: news

Enoxaparin Adjustment Curbs Thromboembolism in Trauma Patients Enoxaparin Adjustment Curbs Thromboembolism in Trauma Patients
In trauma patients, compared to use of standard prophylactic doses of enoxaparin sodium, dosage adjustment prompted by anti-factor Xa (anti-Xa) trough levels may reduce venous thromboembolism (VTE), according to California-based researchers. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 15, 2016 Category: Surgery Tags: Emergency Medicine News Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 7, 2016 Category: Endocrinology Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Pediatric News)
Source: Pediatric News - July 7, 2016 Category: Journals (General) Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Neurology News)
Source: Clinical Neurology News - July 7, 2016 Category: Neurology Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Family Practice News)
Source: Family Practice News - July 7, 2016 Category: Primary Care Source Type: news

Medical errors and the law
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 7, 2016 Category: Endocrinology Source Type: news

Medical errors and the law
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Pediatric News)
Source: Pediatric News - July 7, 2016 Category: Journals (General) Source Type: news

Medical errors and the law
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Neurology News)
Source: Clinical Neurology News - July 7, 2016 Category: Neurology Source Type: news

APEX: Hopeful Sign Despite Betrixaban Miss for VTE PreventionAPEX: Hopeful Sign Despite Betrixaban Miss for VTE Prevention
The novel oral agent didn't win out over enoxaparin in the trial's primary cohort but did in the larger overall cohort; the later finding was exploratory but convincing nonetheless, say researchers. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Betrixaban scores near miss for extended thromboprophylaxis
Extended thromboprophylaxis with the direct factor Xa inhibitor betrixaban just fails to show superiority to standard treatment with enoxaparin in acutely ill medical patients. (Source: MedWire News)
Source: MedWire News - May 31, 2016 Category: Consumer Health News Tags: Thrombosis Source Type: news

Enoxaparin Cost-Effective for Post-Cystectomy VTE Prevention (CME/CE)
(MedPage Today) -- Prophylaxis lowered overall costs, study finds (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 9, 2016 Category: Cardiology Source Type: news

Enoxaparin Sodium Injection (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Teva Bolsters Injectable Portfolio With Launch Of Generic Lovenox And Generic Zyvox In The United States
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, recently announced the launch of the generic equivalent of Lovenox (enoxaparin sodium injection) in seven dosage strengths in the United States (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 23, 2015 Category: Pharmaceuticals Source Type: news

Daiichi Sankyo Begins Phase 3 Study For Edoxaban
Daiichi Sankyo announced that it has initiated enrollment of patients into the multinational Phase III study ENSURE-AF evaluating the safety and efficacy of edoxaban against enoxaparin and warfarin. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 4, 2014 Category: Pharmaceuticals Source Type: news

FDA Underlines Risk of Spinal Procedures on LMW HeparinsFDA Underlines Risk of Spinal Procedures on LMW Heparins
The FDA announced new recommendations aimed at reducing the risk of spinal bleeding with epidural and lumbar puncture procedures among patients taking enoxaparin and other low-molecular-weight heparins. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA updates warning on Sanofi's blood thinner Lovenox
(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding and potential paralysis. (Source: Reuters: Health)
Source: Reuters: Health - November 6, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Bleed Risk Falls with Bivalirudin en Route to PCI for STEMIBleed Risk Falls with Bivalirudin en Route to PCI for STEMI
Some will recognize shades of HORIZONS AMI: the gains came from bivalirudin vs heparin or enoxaparin for STEMI, initiated in EUROMAX while patients were in an ambulance en route to a PCI center. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Apixaban: Effective in Acute VTE; Lower Risk of Major Bleeding
The novel anticoagulant can now be considered for both acute and extended treatment of VTE, with a lower risk of major bleeding than standard treatment with enoxaparin and warfarin. (Source: Consultant Live)
Source: Consultant Live - July 18, 2013 Category: Primary Care Source Type: news

Apixaban vs Standard Anticoagulation in Acute VTEApixaban vs Standard Anticoagulation in Acute VTE
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. (Source: theHeart.org)
Source: theHeart.org - July 1, 2013 Category: Cardiology Source Type: news

STREAM Trial Data Supports An Early Fibrinolysis-Based Strategy For Patients With STEMI Who Cannot Undergo Primary PCI
New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin, followed by timely angiography (pharmaco-invasive strategy), compared to patients given primary PCI after the 60-minute window.(1) "In STEMI patients, the most important thing is to re-establish blood supply to the heart... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

NEJM Paper Confirms Value Of Early Fibrinolysis In STEMI
New England Journal of Medicine (NEJM) paper shows prehospital or early fibrinolysis with Metalyse® (tenecteplase) delivers comparable clinical outcomes to gold standard intervention for patients who would not have access to primary PCI within 60 minutes after the first medical contact(b) New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

RCT: Rivaroxaban for thromboprophylaxis in acutely ill medical patients (MAGELLAN)
Source: N Engl J Med Area: News RCTs of hospitalised patients at increased risk for venous thromboembolism (VTE) have shown the benefits of administering anticoagulant agents for up to 14 days. There is some evidence that the risk of VTE in acutely ill medical patients persists after hospital discharge, but no studies have supported the routine use of extended thromboprophylaxis.   Rivaroxaban is an oral, direct factor Xa inhibitor that is used for the prevention of VTE after elective hip-replacement or knee-replacement surgery in adults. The 'Multicenter, Randomised, Parallel Group Efficacy and Safety Study for ...
Source: NeLM - Cardiovascular Medicine - February 7, 2013 Category: Cardiology Source Type: news

Rivaroxaban Noninferior to Enoxaparin in VTE Prophylaxis, but at a Cost
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 7, 2013 Category: Primary Care Tags: Medical News Source Type: news

Rivaroxaban Reduces VTE Risk in Acutely Ill PatientsRivaroxaban Reduces VTE Risk in Acutely Ill Patients
Rivaroxaban was noninferior to enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism at day 10 and was superior to enoxaparin for the prevention of the same clinical events at day 35. Treatment with the new oral anticoagulant was associated with a significantly increased risk of bleeding at day 10 and day 35, however. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

MAGELLAN published: Rivaroxaban reduces VTE risk in acutely ill patients
Rivaroxaban was noninferior to enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism at day 10 and was superior to enoxaparin for the prevention of the same clinical events at day 35. Treatment with the new oral anticoagulant was associated with a significantly increased risk of bleeding at day 10 and day 35, however. (Source: theHeart.org)
Source: theHeart.org - February 6, 2013 Category: Cardiology Source Type: news

VTE Risk Falls, Bleeds Rise with Longer Prophylaxis (CME/CE)
(MedPage Today) -- Extended treatment with rivaroxaban (Xarelto) resulted in better protection for patients at risk of venous thromboembolism than those treated with a standard course of enoxaparin, a large randomized trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 6, 2013 Category: Cardiology Source Type: news